Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice

Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:FASEB Journal 2011-09, Vol.25 (9), p.3208-3218
Hauptverfasser: Rat, Dorothea, Schmitt, Ulrich, Tippmann, Frank, Dewachter, Ilse, Theunis, Clara, Wieczerzak, Ewa, Postina, Rolf, Van Leuven, Fred, Fahrenholz, Falk, Kojro, Elzbieta
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3218
container_issue 9
container_start_page 3208
container_title FASEB Journal
container_volume 25
creator Rat, Dorothea
Schmitt, Ulrich
Tippmann, Frank
Dewachter, Ilse
Theunis, Clara
Wieczerzak, Ewa
Postina, Rolf
Van Leuven, Fred
Fahrenholz, Falk
Kojro, Elzbieta
description Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_354447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_354447</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_3544473</originalsourceid><addsrcrecordid>eNqNjMFOwzAQRH0AiVL4B98KQpGcJk3TY1SBOKEeuEcrZ0mXOrZlb1rM5_ClBInee5rRaN67EjNVb5ZZVRX1jbiN8VMplau8momfNxyD8-iZOpSeeCSGkCR0aJMBRqmTNhAxA810BCbbS-9MOiMPu2bb7B5lNO4UZedOVjbme480YFhMA0X8ow0dJj3w3hnXJ0lWwpCMo076gHoM0YWpOUayGQewsUdLWg6k8U5cf4CJeP-fc7F4eX7fvmaH0eB4RNt20YPGNl8W5apa15u2WJVluS7m4umyZ8tfXFzu_QVOxGzj</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</title><source>Lirias (KU Leuven Association)</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Rat, Dorothea ; Schmitt, Ulrich ; Tippmann, Frank ; Dewachter, Ilse ; Theunis, Clara ; Wieczerzak, Ewa ; Postina, Rolf ; Van Leuven, Fred ; Fahrenholz, Falk ; Kojro, Elzbieta</creator><creatorcontrib>Rat, Dorothea ; Schmitt, Ulrich ; Tippmann, Frank ; Dewachter, Ilse ; Theunis, Clara ; Wieczerzak, Ewa ; Postina, Rolf ; Van Leuven, Fred ; Fahrenholz, Falk ; Kojro, Elzbieta</creatorcontrib><description>Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org</description><identifier>ISSN: 0892-6638</identifier><language>eng</language><publisher>9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA: The Federation of American Societies for Experimental Biology</publisher><ispartof>FASEB Journal, 2011-09, Vol.25 (9), p.3208-3218</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,27837</link.rule.ids></links><search><creatorcontrib>Rat, Dorothea</creatorcontrib><creatorcontrib>Schmitt, Ulrich</creatorcontrib><creatorcontrib>Tippmann, Frank</creatorcontrib><creatorcontrib>Dewachter, Ilse</creatorcontrib><creatorcontrib>Theunis, Clara</creatorcontrib><creatorcontrib>Wieczerzak, Ewa</creatorcontrib><creatorcontrib>Postina, Rolf</creatorcontrib><creatorcontrib>Van Leuven, Fred</creatorcontrib><creatorcontrib>Fahrenholz, Falk</creatorcontrib><creatorcontrib>Kojro, Elzbieta</creatorcontrib><title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</title><title>FASEB Journal</title><description>Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org</description><issn>0892-6638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqNjMFOwzAQRH0AiVL4B98KQpGcJk3TY1SBOKEeuEcrZ0mXOrZlb1rM5_ClBInee5rRaN67EjNVb5ZZVRX1jbiN8VMplau8momfNxyD8-iZOpSeeCSGkCR0aJMBRqmTNhAxA810BCbbS-9MOiMPu2bb7B5lNO4UZedOVjbme480YFhMA0X8ow0dJj3w3hnXJ0lWwpCMo076gHoM0YWpOUayGQewsUdLWg6k8U5cf4CJeP-fc7F4eX7fvmaH0eB4RNt20YPGNl8W5apa15u2WJVluS7m4umyZ8tfXFzu_QVOxGzj</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Rat, Dorothea</creator><creator>Schmitt, Ulrich</creator><creator>Tippmann, Frank</creator><creator>Dewachter, Ilse</creator><creator>Theunis, Clara</creator><creator>Wieczerzak, Ewa</creator><creator>Postina, Rolf</creator><creator>Van Leuven, Fred</creator><creator>Fahrenholz, Falk</creator><creator>Kojro, Elzbieta</creator><general>The Federation of American Societies for Experimental Biology</general><scope>FZOIL</scope></search><sort><creationdate>201109</creationdate><title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</title><author>Rat, Dorothea ; Schmitt, Ulrich ; Tippmann, Frank ; Dewachter, Ilse ; Theunis, Clara ; Wieczerzak, Ewa ; Postina, Rolf ; Van Leuven, Fred ; Fahrenholz, Falk ; Kojro, Elzbieta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_3544473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rat, Dorothea</creatorcontrib><creatorcontrib>Schmitt, Ulrich</creatorcontrib><creatorcontrib>Tippmann, Frank</creatorcontrib><creatorcontrib>Dewachter, Ilse</creatorcontrib><creatorcontrib>Theunis, Clara</creatorcontrib><creatorcontrib>Wieczerzak, Ewa</creatorcontrib><creatorcontrib>Postina, Rolf</creatorcontrib><creatorcontrib>Van Leuven, Fred</creatorcontrib><creatorcontrib>Fahrenholz, Falk</creatorcontrib><creatorcontrib>Kojro, Elzbieta</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>FASEB Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rat, Dorothea</au><au>Schmitt, Ulrich</au><au>Tippmann, Frank</au><au>Dewachter, Ilse</au><au>Theunis, Clara</au><au>Wieczerzak, Ewa</au><au>Postina, Rolf</au><au>Van Leuven, Fred</au><au>Fahrenholz, Falk</au><au>Kojro, Elzbieta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</atitle><jtitle>FASEB Journal</jtitle><date>2011-09</date><risdate>2011</risdate><volume>25</volume><issue>9</issue><spage>3208</spage><epage>3218</epage><pages>3208-3218</pages><issn>0892-6638</issn><abstract>Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org</abstract><cop>9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA</cop><pub>The Federation of American Societies for Experimental Biology</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0892-6638
ispartof FASEB Journal, 2011-09, Vol.25 (9), p.3208-3218
issn 0892-6638
language eng
recordid cdi_kuleuven_dspace_123456789_354447
source Lirias (KU Leuven Association); Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection
title Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A23%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuropeptide%20pituitary%20adenylate%20cyclase-activating%20polypeptide%20(PACAP)%20slows%20down%20Alzheimer's%20disease-like%20pathology%20in%20amyloid%20precursor%20protein-transgenic%20mice&rft.jtitle=FASEB%20Journal&rft.au=Rat,%20Dorothea&rft.date=2011-09&rft.volume=25&rft.issue=9&rft.spage=3208&rft.epage=3218&rft.pages=3208-3218&rft.issn=0892-6638&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_354447%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true